Skip to content

Depression research published in 2025

Page 30 of 39: studies 581 to 600 of 761, newest first. Back to the depression overview

Studies

Improving Maternal Mental Health and Weight Control With a Mindfulness Blended Care Approach: Insights From a Randomized Controlled Trial.

Journal of Medical Internet Research February 24, 2025 Kathrin Hassdenteufel, Mitho Müller, Harald Abele et al. 1 citation

Perinatal maternal mental health problems, such as depression and anxiety, are highly prevalent during pregnancy and post partum. Electronic mindfulness-based interventions (eMBIs) are a promising treatment option, which can be provided in a low-threshold, cost-effective manner. However, research underscores the fact that face-to-face coaching sessions are more effective than solely digital...

Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.

Journal of Psychoactive Drugs February 20, 2025 Broc A. Pagni, Andreas Halman, Jerome Sarris et al. 7 citations

The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...

Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms.

Annual Review of Neuroscience February 19, 2025 Macauley Smith Breault, Sirma Orguc, Ohyoon Kwon et al. 13 citations

Major depressive disorder and treatment-resistant depression are significant worldwide health problems that need new therapies. The success of the anesthetic ketamine as an antidepressant is well known. It is less widely known that several other anesthetic agents have also shown antidepressant effects. These include nitrous oxide, propofol, isoflurane, sevoflurane, dexmedetomidine, and xenon....

DOI: 10.1146/annurev-neuro-112723-062031 (opens in new tab) Full text (opens in new tab) Depression treatment Anesthesia research Mental health breakthroughs Drug repurposing

9 THE CLINICAL INTERVENTION EFFECT OF MINDFULNESS PAINTING ART THERAPY ON ADOLESCENT DEPRESSION PATIENTS

Schizophrenia Bulletin February 18, 2025 Yujia Zhai

Abstract Background With the arrival of the new era, teenagers face enormous academic and life pressures, which are accompanied by various psychological and physiological problems, and in severe cases, even depression. Depression can affect various aspects of people’s lives and is gradually becoming younger, with teenagers experiencing more severe depression problems. Therefore, it is necessary...

Comparative Efficacy and Safety of Ketamine Versus Electroconvulsive Therapy in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

Psychiatric Quarterly February 18, 2025 Zhijian Ma, Fengle Wu, Wen Zheng 4 citations

This meta-analysis aimed to compare the efficacy and safety of ketamine versus electroconvulsive therapy (ECT) in patients with major depressive disorder(MDD). A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases up to November 2024. The randomized controlled trials evaluating the efficacy and safety of ketamine and ECT in MDD patients were...

Esketamine reduces postoperative depression in breast cancer through TREK-1 channel inhibition and neurotransmitter modulation.

Cancer cell international February 18, 2025 Jiachi Xu, Mingcan Li, Yu Hu et al. 6 citations

Postoperative depression significantly affects the quality of life of breast cancer patients. This study explores the potential therapeutic effects of esketamine on postoperative depression through modulation of the TREK-1 two-pore domain potassium channel. We analyzed data from 54 female breast cancer patients who underwent surgery at our hospital between 2019 and 2023, dividing them into...

DOI: 10.1186/s12935-025-03664-7 (opens in new tab) Full text (opens in new tab) Breast cancer Hippocampal neurons Postoperative depression Trek-1 channels +7

Ketamine in the Treatment of Depression

Journal of Education, Health and Sport February 17, 2025 Urszula Kaczmarska, Michał Jakub Cioch, Julia Nowak et al.

Introduction Depression is one of the most common mental illnesses. Over the course of a lifetime, several percent of the adult population suffers from depression. There are many treatments for depression like pharmacotherapy and psychotherapy. In this article, we wanted to focus on the effectiveness of ketamine in treating depression. Aim of study The study aimed to summarize the available...

Esketamine alleviates LPS-induced depression-like behavior by activating Nrf2-mediated anti-inflammatory response in adolescent mice.

Neuroscience February 16, 2025 Xinxu Ma, Shanshan Xue, Hongzhe Ma et al. 12 citations

The mechanisms underlying esketamine's therapeutic effects remain elusive. The study aimed to explore the impact of single esketamine treatment on LPS-induced adolescent depressive-like behaviors and the role of Nrf2 regulated neuroinflammatory response in esketamine-produced rapid antidepressant efficacy. Adolescent male C57BL/6J mice were randomly assigned to three groups: control, LPS, and...

DOI: 10.1016/j.neuroscience.2024.12.062 (opens in new tab) Full text (opens in new tab) Depression treatment Antidepressants Mental health Inflammation

Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.

Journal of Affective Disorders February 15, 2025 Zhan-Ming Shi, Xian-Jun Lan, Qing Chen et al. 6 citations

Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. Randomized controlled...

Penggunaan Mindfulness-Based Cognitive Therapy (MBCT) untuk Menurunkan Gejala Depresi Wanita dengan (Major Depressive Disorder (MDD)

JIIP - Jurnal Ilmiah Ilmu Pendidikan February 13, 2025 Hasrat Listaria Mailana, Ika Yuniar Cahyanti

Gangguan Depresi Mayor (Major Depressive Disorder/MDD) secara klinis ditandai dengan kehilangan minat dan kesulitan untuk merasa kepuasan dan kebahagiaan dalam kesehariannya. Kondisi ini harus berlangsung setidaknya 2 minggu atau lebih dan memengaruhi keberfungsian individu dalam keseharian. Individu yang mengalami gangguan ini biasanya terjebak dalam pemikiran yang negatif dan melakukan...

Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.

ACS Medicinal Chemistry Letters February 13, 2025 Ram W. Sabnis, Anika R. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.

Effectiveness of an Internet-Based, Self-Guided, Short-Term Mindfulness Training (ISSMT) Program for Relieving Depressive Symptoms in the Adult Population in China: Single-Blind, Randomized Controlled Trial.

Journal of Medical Internet Research February 13, 2025 Tingfei Zhu, Liuyi Zhang, Wenqi Weng et al. 4 citations

Depression is a significant global public health issue, and in China, access to mental health services remains limited despite high demand. Research has shown that mindfulness can effectively alleviate depressive symptoms and that telehealth solutions offer a promising avenue for addressing this service gap. Despite this potential, there are currently few studies in China focusing on short-term...

Effect of technology-supported mindfulness-based interventions for maternal depression: a systematic review and meta-analysis with implementation perspectives for resource-limited settings.

BMC Pregnancy and Childbirth February 13, 2025 Bekelu Teka Worku, Misra Abdulahi, Demissew Amenu et al. 9 citations

Maternal depression is pregnancy and childbirth-related depression during pregnancy (prenatal depression (PND)) or after delivery (postpartum depression (PPD)). It is a recognized global public health concern with extensive repercussions adversely affecting women's well-being and the developmental progress of infants. Mindfulness-based interventions (MBIs) have been shown to be effective in...

DOI: 10.1186/s12884-025-07286-9 (opens in new tab) Full text (opens in new tab) Maternal depression Meta-analysis Mindfulness-based interventions Perinatal depression +4

SLOW BUT STEADY: ORAL KETAMINE AS AN EFFECTIVE ADJUNCT IN DEPRESSION, ANXIETY AND PTSD

The International Journal of Neuropsychopharmacology February 12, 2025 *William Sulis

Abstract Intravenous and intranasal Ketamine have become important options for the rapid relief of symptoms in PTSD, Suicidality and in Treatment Resistant Depression and Anxiety. However, they are costly, require at least an out- patient clinic setting and have relatively short lived benefits. I present a pilot study examining 8 patients treated with oral Ketamine, 5 mg/kg for 12 treatments....

METHOXPHENIDINE, A DESIGNER DRUG OR A POSSIBLE ROUTE FOR RESEARCH TO DEPRESSION TREATMENT?

The International Journal of Neuropsychopharmacology February 12, 2025 *Bronislav Jurásek, Magdaléna Vágnerová, Hana Walaská et al.

Abstract Background Methoxphenidine (MXP) is a new psychoactive substance that belongs to the group of arylethylamines. Even though MXP has a different pharmacophore than ketamine, both of these substances belong to the dissociatives. To date, MXP has been associated with several intoxications and despite it being banned in most countries it is still available over the internet.1 Aims &...

Is ketamine efficacious for rapid treatment of acute suicidal ideation in an emergency setting? Lessons learned from a pilot randomized controlled trial.

BMC research notes February 12, 2025 Maryam Barzkar, Kaveh Alavi, Kazem Malakouti et al. 1 citation

This study aimed to evaluate the efficacy of a single infusion of ketamine in inducing rapid remission of severe suicidal ideation, compared to Midazolam, in a population with acute suicidal thoughts. In a double-blind randomized controlled trial conducted in Tehran, Iran, from January to July 2022 (IRCT20220118053756N1), 36 inpatients with acute severe suicidal ideation were enrolled....

Dynamical repertoire of brain networks in mindfulness cognitive behavioural therapy during rumination: A randomized controlled trial

medRxiv February 7, 2025 Jakub Vohryzek, Anne Maj van der Velden, Willem Kuyken et al. 1 citation preprint

BACKGROUND: Depression is a prevalent and debilitating affective disorder characterised by the dominance and persistence of depressive rumination. Mindfulness-based cognitive therapy (MBCT) is an effective treatment for recurrent depression developed specifically to target rumination and recurrence risk by training metacognitive awareness and adaptive attention, emotion and self-regulation...

Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis.

BMC Pregnancy and Childbirth February 6, 2025 Moaz Yasser Darwish, Abdallah A Helal, Yousif Ahmed Othman et al. 8 citations

Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests that they may have a role in the prevention of PPD. This systematic review and meta-analysis aim to update evidence...

DOI: 10.1186/s12884-025-07186-y (opens in new tab) Full text (opens in new tab) Esketamine Mental health Postpartum depression ppd Antidepressants +2

Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges

Brain Sciences February 6, 2025 Michael J Lucido, Boadie W Dunlop 15 citations

Background/Objectives: Non-response to initial treatment options for major depressive disorder (MDD) is a common clinical challenge with profound deleterious impacts for affected patients. Few treatments have received regulatory approval for treatment-resistant depression (TRD). Methods: A systematic search of United States and European Union clinical trials registries was conducted to identify...

DOI: 10.3390/brainsci15020161 (opens in new tab) Psilocybin Depression treatment antidepressants Therapy Medication +12